Literature DB >> 21616283

Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function.

Kevin Damman1, Marie J Ng Kam Chuen, Robert J MacFadyen, Gregory Y H Lip, David Gaze, Paul O Collinson, Hans L Hillege, Wim van Oeveren, Adriaan A Voors, Dirk J van Veldhuisen.   

Abstract

OBJECTIVES: This study sought to determine the pharmacodynamic effect of modulation of volume status by withdrawal and reinstitution of diuretic treatment on markers of renal and tubular function.
BACKGROUND: Decreased renal perfusion and increased congestion are associated with renal dysfunction in patients with heart failure.
METHODS: In this study, 30 patients with chronic systolic heart failure in a presumed euvolemic state and on standard oral furosemide therapy (40 to 80 mg) were examined. At baseline, subjects were withdrawn from their loop diuretics. After 72 h, their furosemide regimen was reinstated, and patients were studied again 3 days later. Serum creatinine, atrial and B-type natriuretic peptide, urinary kidney injury molecule (KIM)-1, urinary N-acetyl-beta-D-glucosaminidase (NAG), and serum as well as urinary neutrophil gelatinase-associated lipocalin (NGAL) were determined at various time points.
RESULTS: Diuretic withdrawal resulted in increases in atrial and B-type natriuretic peptide (both p < 0.05). Serum creatinine was unaffected. Both urinary KIM-1 (p < 0.001) and NAG (p = 0.010) concentrations rose significantly, after diuretic withdrawal, whereas serum and urinary NGAL were not significantly affected. After reinitiation of furosemide, both urinary KIM-1 and NAG concentrations returned to baseline (both p < 0.05), but NGAL values were unaffected.
CONCLUSIONS: Subclinical changes in volume status by diuretic withdrawal and reinstitution are associated with increases and decreases of markers of tubular dysfunction in stable heart failure. Diuretic therapy may favorably affect renal and tubular function by decreasing congestion.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21616283     DOI: 10.1016/j.jacc.2010.10.065

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  36 in total

1.  Management of the cardiorenal syndrome in acute heart failure.

Authors:  Valentina Lazzarini; G Michael Felker
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 2.  Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure.

Authors:  Mihai Gheorghiade; Muthiah Vaduganathan; Andrew Ambrosy; Michael Böhm; Umberto Campia; John G F Cleland; Francesco Fedele; Gregg C Fonarow; Aldo P Maggioni; Alexandre Mebazaa; Mandeep Mehra; Marco Metra; Savina Nodari; Peter S Pang; Piotr Ponikowski; Hani N Sabbah; Michel Komajda; Javed Butler
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

Review 3.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

Review 4.  Clinical utility of antigen carbohydrate 125 in heart failure.

Authors:  Julio Núñez; Gema Miñana; Eduardo Núñez; Francisco J Chorro; Vicent Bodí; Juan Sanchis
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

Review 5.  Remote Monitoring to Reduce Heart Failure Readmissions.

Authors:  Sitaramesh Emani
Journal:  Curr Heart Fail Rep       Date:  2017-02

Review 6.  The kidney in heart failure: an update.

Authors:  Kevin Damman; Jeffrey M Testani
Journal:  Eur Heart J       Date:  2015-04-02       Impact factor: 29.983

Review 7.  The role of the kidney in acute and chronic heart failure.

Authors:  Gaetano Ruocco; Alberto Palazzuoli; Jozine M Ter Maaten
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

8.  Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events.

Authors:  Sean P Collins; Kimberly W Hart; Christopher J Lindsell; Gregory J Fermann; Neal L Weintraub; Karen F Miller; Susan N Roll; Matthew I Sperling; Douglas B Sawyer; Alan B Storrow
Journal:  Eur J Heart Fail       Date:  2012-06-25       Impact factor: 15.534

Review 9.  Redefining biomarkers in heart failure.

Authors:  Michele Correale; Ilenia Monaco; Natale Daniele Brunetti; Matteo Di Biase; Marco Metra; Savina Nodari; Javed Butler; Mihi Gheorghiade
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

Review 10.  Epidemiology and importance of renal dysfunction in heart failure patients.

Authors:  Gregory Giamouzis; Andreas P Kalogeropoulos; Javed Butler; Georgios Karayannis; Vasiliki V Georgiopoulou; John Skoularigis; Filippos Triposkiadis
Journal:  Curr Heart Fail Rep       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.